Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P0EQ | ISIN: US7027121000 | Ticker-Symbol:
NASDAQ
27.06.25 | 21:38
0,340 US-Dollar
+3,03 % +0,010
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PASSAGE BIO INC Chart 1 Jahr
5-Tage-Chart
PASSAGE BIO INC 5-Tage-Chart

Aktuelle News zur PASSAGE BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoPassage Bio reports updated data on PBFT02 for FTD treatment-
MoPassage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update116PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose...
► Artikel lesen
MoPassage BIO, Inc. - 8-K, Current Report1
30.05.Passage BIO, Inc. - 8-K, Current Report2
13.05.Passage Bio GAAP EPS of -$0.25 misses by $0.021
13.05.Passage BIO, Inc. - 10-Q, Quarterly Report-
PASSAGE BIO Aktie jetzt für 0€ handeln
13.05.Passage BIO, Inc. - 8-K, Current Report1
05.03.Passage BIO, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
04.03.Chardan cuts Passage Bio stock price target to $6, maintains buy12
04.03.PASSAGE BIO, INC. Full Year Loss Decreases-
04.03.Passage Bio GAAP EPS of -$1.07 misses by $0.123
04.03.Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights133Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history...
► Artikel lesen
04.03.Passage BIO, Inc. - 10-K, Annual Report-
04.03.Passage BIO, Inc. - 8-K, Current Report-
31.01.Passage BIO, Inc. - 8-K, Current Report-
10.01.IGM, Y-mAbs, Passage Bio and more telegraph staff cuts amid restructuring spree2
10.01.Passage BIO, Inc. - 8-K, Current Report-
01.08.24Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration133Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biotherapeutics...
► Artikel lesen
16.07.24Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients107Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Plan...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1